Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study

Douglas Tremblay; Abiola O. Oladapo; Emily Levine; Michael Marrone; Djibril Liassou; Purvi Suthar; Adina Geprifti; Gerard Hoehn; Michael Vredenburg; Bruce Feinberg; Naveen Pemmaraju; James Rossetti

doi:10.67209/wpqr5260

Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study

NCODA Oncology and Hematology Meeting Abstracts 2026

View at publisher

Authors: Douglas Tremblay, Abiola O. Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg, Bruce Feinberg, Naveen Pemmaraju, James Rossetti

DOI: 10.67209/wpqr5260

Cited by: 1

References: 4

Abstract

Pacritinib (PAC), a JAK1 sparing JAK2/IRAK1/ ACVR1 inhibitor is approved for patients with myelofibrosis (MF) and severe thrombocytopenia (platelet [PLT] counts

Publication details

Journal / source: NCODA Oncology and Hematology Meeting Abstracts
Publication date: 15 June 2026

References 4